CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

News Charles River Laboratories International, Inc.

Stocks

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - NYSE 21:00:03 16/10/2026 BST			5-day change	1st Jan Change
300.15 ^USD	-1.99%		-0.54%	+50.47%

10-14	JPMorgan Adjusts Price Target on Charles River Laboratories International to $345 From $310	MT
10-13	Magellan Stem Cells Collaborates with Charles River Laboratories International, Inc. to Advance Stem Cell and Regenerative Medicine Development	CI

All News

Mentions Relevance

10-14	JPMorgan Adjusts Price Target on Charles River Laboratories International to $345 From $310	MT
10-13	Magellan Stem Cells Collaborates with Charles River Laboratories International, Inc. to Advance Stem Cell and Regenerative Medicine Development	CI
10-13	Charles River Laboratories Working With Magellan Stem Cells to Test Osteoarthritis Therapy	MT
10-13	Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development	BU
10-12	Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $340 From $300	MT
10-09	Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call	BU
10-06	Charles River Laboratories International, Inc. and Autolomous Launch Apollo Orchestrate Within Charles River's Apollo Platform	CI
10-06	Charles River and Autolomous Partner to Transform Laboratory Execution Systems	BU
09-30	UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175	MT
09-28	Jefferies Adjusts PT on Charles River Laboratories International to $340 From $305, Maintains Buy Rating	MT
09-25	Charles River Laboratories's DAS Segment Faces Largest Margin Upside, RBC Says	MT
09-25	Deutsche Bank Raises Price Target on Charles River Laboratories International to $320 From $300, Keeps Buy Rating	MT
09-25	RBC Raises Price Target on Charles River Laboratories International to $322 From $282, Keeps Outperform Rating	MT
09-25	Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating	MT
09-25	Mizuho Adjusts PT on Charles River Laboratories International to $295 From $264, Keeps Neutral Rating	MT
09-25	Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating	MT
09-25	TD Cowen Adjusts PT on Charles River Laboratories International to $325 From $300, Maintains Buy Rating	MT
09-25	Baird Adjusts PT on Charles River Laboratories International to $334 From $291, Keeps Outperform Rating	MT
09-24	Charles River Laboratories International, Inc. - Analyst/Investor Day
09-24	Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections	MT
09-24	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS at Upper End of $11.15 - $11.45, vs. FactSet Est of $11.33	MT
09-24	Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day	BU
09-17	Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization	CI
09-17	Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating	MT
09-17	Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines	BU